FDA extends review process for Oleogel-S10

24 November 2021
amryt_large_2021

The US Food and Drug Administration has extended the review period for the New Drug Application (NDA) for Oleogel-S10 for the treatment of the cutaneous manifestations of junctional and dystrophic bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.

The NDA was filed by Ireland headquartered rare diseases firm Amryt Pharma (AIM: AMYT) in March this year. The drug, trade named Filsuvez, is also under review with the European Medicines Agency. The news sent Amryt’s New York traded shares down more than 10% to $10.8 by close of trading on Tuesday.

The FDA extended the Prescription Drug User Fee Act (PDUFA) goal date to allow time to review additional analyses of data previously submitted by Amryt. The submission of this additional information has been determined by the FDA to constitute a Major Amendment to the NDA, resulting in an extension of the PDUFA goal date by three months to February 28, 2022.  This is a standard review extension period to allow the FDA additional time to review information already submitted by Amryt. At the same time, the FDA also issued a new Information Request regarding existing study data in order to continue the FDA’s evaluation of Amryt’s NDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical